Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb

US9951106B2 · kind B2 · utility

Assignee

• UNIVERSITY OF MARYLAND, BALTIMORE · US

Inventors

• Yongjun Guan · Clarksville, US
• George K. Lewis · Baltimore, US
• Anthony DeVico · Alexandria, US
• Mohammad Sajadi · Cockeysville, US
• Tongyun Liu · Edgewood, US
• Marzena PAZGIER · Mount Airy, US

Key dates

• Filing date: Dec 4, 2013
• Grant date: Apr 24, 2018
• Expiry date: Dec 4, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16134
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Fusion proteins comprising a portion of the HIV-1 Env protein (gp120 and gp140) and single-chain fragment V regions (ScFv) of an enhancing antibody that exhibits binding specificity for HIV-1 Env protein are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection, as well as methods of generating an immune response using the fusion proteins.